329.0K XNAS Volume
XNAS 17 Apr, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Matthew L. Wein | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 22,725 | 22,725 | - | - | Stock Option (Right to Buy) | |
| Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 14,000 | 114,374 | - | 0 | Common Stock | |
| Pamela Wapnick | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 14,000 | 73,684 | - | 0 | Common Stock | |
| Pamela Wapnick | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Brian C. Thomas | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 196,000 | 196,000 | - | - | Stock Option (Right to Buy) | |
| Brian C. Thomas | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 32,000 | 2,528,276 | - | 0 | Common Stock | |
| Jian Irish | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 23,000 | 321,933 | - | 0 | Common Stock | |
| Jian Irish | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Matthew L. Wein | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 21,875 | 21,875 | - | - | Stock Option (Right to Buy) | |
| Matthew L. Wein | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 3,775 | 16,892 | - | 0 | Common Stock | |
| Matthew L. Wein | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 3,650 | 13,117 | - | 0 | Common Stock | |
| Matthew L. Wein | See Remarks | Sale of securities on an exchange or to another person at price $ 1.88 per share. | 05 Mar 2025 | 930 | 9,467 | - | 1.9 | 1,744 | Common Stock |
| Pamela Wapnick | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.88 per share. | 05 Mar 2025 | 1,808 | 59,684 | - | 1.9 | 3,390 | Common Stock |
| Eric H. Bjerkholt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Wapnick Pamela | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.86 per share. | 05 Dec 2024 | 1,559 | 61,492 | - | 1.9 | 2,900 | Common Stock |
| Wapnick Pamela | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.88 per share. | 05 Sep 2024 | 6,265 | 63,051 | - | 2.9 | 18,043 | Common Stock |
| Luis G. Borges | Chief Scientific Officer | 01 Apr 2024 | 291,450 | 291,450 | - | - | Stock Option (Right to Buy) | ||
| Simon Harnest | See Remarks | 01 Apr 2024 | 48,575 | 48,575 | - | - | Stock Option (Right to Buy) | ||
| Willard H. Dere | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 78,636 | 78,636 | - | - | Stock Option (Right to Buy) | |
| Luis G. Borges | Chief Scientific Officer | 01 Apr 2024 | 69,316 | 69,316 | - | 0 | Common Stock | ||
| Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 242,875 | 242,875 | - | - | Stock Option (Right to Buy) | |
| Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 57,763 | 100,374 | - | 0 | Common Stock | |
| Pamela Wapnick | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 291,450 | 291,450 | - | - | Stock Option (Right to Buy) | |
| Pamela Wapnick | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 69,316 | 69,316 | - | 0 | Common Stock | |
| Juergen Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 78,636 | 78,636 | - | - | Stock Option (Right to Buy) | |
| Brian C. Thomas | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 118,992 | 2,496,276 | - | 0 | Common Stock | |
| Brian C. Thomas | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 500,323 | 500,323 | - | - | Stock Option (Right to Buy) | |
| Jian Irish | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 70,471 | 298,933 | - | 0 | Common Stock | |
| Jian Irish | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 296,308 | 296,308 | - | - | Stock Option (Right to Buy) | |
| Simon Harnest | See Remarks | 01 Apr 2024 | 11,552 | 122,664 | - | 0 | Common Stock | ||
| Matthew L. Wein | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 43,717 | 43,717 | - | - | Stock Option (Right to Buy) | |
| Simren Delaney | See Remarks | 01 Apr 2024 | 29,145 | 29,145 | - | - | Stock Option (Right to Buy) | ||
| Simren Delaney | See Remarks | 01 Apr 2024 | 6,931 | 93,892 | - | 0 | Common Stock | ||
| Sebastian Bernales | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 78,636 | 78,636 | - | - | Stock Option (Right to Buy) | |
| Matthew L. Wein | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 10,397 | 10,397 | - | 0 | Common Stock | |
| Sebastian Bernales | Director | 13 Feb 2024 | 106,627 | 0 | - | - | Series B-1 Preferred Stock | ||
| Sebastian Bernales | Director | 13 Feb 2024 | 2,062,387 | 0 | - | - | Series A-4 Preferred Stock | ||
| Sebastian Bernales | Director | 13 Feb 2024 | 423,469 | 0 | - | - | Series A-4 Preferred Stock | ||
| Sebastian Bernales | Director | 13 Feb 2024 | 119,699 | 0 | - | - | Series A-3 Preferred Stock | ||
| Sebastian Bernales | Director | 13 Feb 2024 | 353,005 | 0 | - | - | Series A-2 Preferred Stock | ||
| Sebastian Bernales | Director | 13 Feb 2024 | 1,896,445 | 1,896,445 | - | - | Common Stock | ||
| Sebastian Bernales | Director | 13 Feb 2024 | 513,004 | 769,845 | - | - | Common Stockc | ||
| Sebastian Bernales | Director | 13 Feb 2024 | 1,143,905 | 0 | - | - | Series B Preferred Stock |